Gene Expression of Endothelin-1 and Endothelin Receptor a on Monocrotaline-induced Pulmonary Hypertension in Rats After Bosentan Treatment

Overview

Journal Korean Circ J

Date 2010 Oct 23

PMID 20967148

Citations 13

Authors

Kyoung Ah Lim

Kwan Chang Kim

Min-Sun Cho

Bo En Lee

Hae Soon Kim

Young Mi Hong

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: Endothelin (ET)-1, a potent endothelium-derived vasoconstrictor peptide, has a potential pathophysiologic role in pulmonary hypertension. Bosentan, a dual ET receptor (ET(A)/ET(B)) antagonist, is efficacious in treatment of pulmonary hypertension. The objectives of this study were to investigate the expression of ET-1 and ET receptor A (ERA) genes and to evaluate the effect of bosentan in monocrotaline (MCT)-induced pulmonary hypertension.

Materials And Methods: Four-week-old male Sprague-Dawley rats were treated as follows: control (n=36), subcutaneous (sc) injection of saline; MCT (n=36), sc injection of MCT (60 mg/kg); and bosentan (n=36), sc injection of MCT (60 mg/kg) plus 25 mg/kg/day bosentan orally.

Results: Serum ET-1 concentrations in the MCT group were higher than the control group on day 28 and 42. Quantitative analysis of peripheral pulmonary arteries revealed that the increase in medial wall thickness after MCT injection was significantly attenuated in the bosentan group on day 28 and 42. In addition, the increase in the number of intra-acinar muscular arteries after MCT injection was reduced by bosentan on day 14, 28 and 42. The levels of ET-1 and ERA gene expression were significantly increased in the MCT group compared with control group on day 5, and bosentan decreased the expression of ET-1 on day 5.

Conclusion: ET-1 contributes to the progression of cardiopulmonary pathology in rats with MCT-induced pulmonary hypertension. Administration of bosentan reduced ET-1 gene expression in MCT-induced pulmonary hypertension in rats.

Citing Articles

A Bioinformatic Algorithm based on Pulmonary Endoarterial Biopsy for Targeted Pulmonary Arterial Hypertension Therapy.

Rothman A, Mann D, Nunez J, Tarmidi R, Restrepo H, Sarukhanov V Open Respir Med J. 2024; 17:e187430642308160.

PMID: 38655076 PMC: 11037516. DOI: 10.2174/18743064-v17-230927-2023-9.

Novel Genome-Wide Interactions Mediated via BOLL and EDNRA Polymorphisms in Intracranial Aneurysm.

Hong E, Youn D, Kim B, Lee J, Nam S, Yoo H J Korean Neurosurg Soc. 2022; 66(4):409-417.

PMID: 36274247 PMC: 10323267. DOI: 10.3340/jkns.2022.0026.

Effect of Ambrisentan Therapy on the Expression of Endothelin Receptor, Endothelial Nitric Oxide Synthase and NADPH Oxidase 4 in Monocrotaline-induced Pulmonary Arterial Hypertension Rat Model.

Lee H, Yeom A, Kim K, Hong Y Korean Circ J. 2019; 49(9):866-876.

PMID: 31165592 PMC: 6713827. DOI: 10.4070/kcj.2019.0006.

Modafinil improves monocrotaline-induced pulmonary hypertension rat model.

Lee H, Kim K, Cho M, Suh S, Hong Y Pediatr Res. 2016; 80(1):119-27.

PMID: 26959484 DOI: 10.1038/pr.2016.38.

Transfer of human hepatocyte growth factor reduces inflammation and prevents pulmonary arterial remodeling in monocrotaline-induced.

Chen J, Zhang H, Zhang R, Liu Z, Wang J, Xiao M Int J Clin Exp Pathol. 2015; 7(12):8763-9.

PMID: 25674243 PMC: 4313970.

References

Schermuly R, Kreisselmeier K, Ghofrani H, Yilmaz H, Butrous G, Ermert L . Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med. 2003; 169(1):39-45. DOI: 10.1164/rccm.200302-282OC. View

Vane J . Endothelins come home to roost. Nature. 1990; 348(6303):673. DOI: 10.1038/348673a0. View

Clozel M, Hess P, Rey M, Iglarz M, Binkert C, Qiu C . Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats. Exp Biol Med (Maywood). 2006; 231(6):967-73. View

Prie S, Leung T, Cernacek P, Ryan J, Dupuis J . The orally active ET(A) receptor antagonist (+)-(S)-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphe nyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in.... J Pharmacol Exp Ther. 1997; 282(3):1312-8. View

Morice A, Mulrennan S, Clark A . Combination therapy with bosentan and phosphodiesterase-5 inhibitor in pulmonary arterial hypertension. Eur Respir J. 2005; 26(1):180. DOI: 10.1183/09031936.05.00030405. View

Sakurai T, Yanagisawa M, Masaki T . Molecular characterization of endothelin receptors. Trends Pharmacol Sci. 1992; 13(3):103-8. DOI: 10.1016/0165-6147(92)90038-8. View

Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S . Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990; 348(6303):730-2. DOI: 10.1038/348730a0. View

Tuder R, Marecki J, Richter A, Fijalkowska I, Flores S . Pathology of pulmonary hypertension. Clin Chest Med. 2007; 28(1):23-42, vii. PMC: 1924722. DOI: 10.1016/j.ccm.2006.11.010. View

Park H, Park S, Kim C, Paek Y, Lee J, Lee W . Enhanced gene expression of renin-angiotensin system, TGF-beta1, endothelin-1 and nitric oxide synthase in right-ventricular hypertrophy. Pharmacol Res. 2001; 43(3):265-73. DOI: 10.1006/phrs.2000.0777. View

10.

Loffler B, Breu V, Clozel M . Effect of different endothelin receptor antagonists and of the novel non-peptide antagonist Ro 46-2005 on endothelin levels in rat plasma. FEBS Lett. 1993; 333(1-2):108-10. DOI: 10.1016/0014-5793(93)80384-7. View

11.

Kim H, Yung G, Marsh J, Konopka R, Pedersen C, Chiles P . Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension. Eur Respir J. 2000; 15(4):640-8. DOI: 10.1034/j.1399-3003.2000.15d04.x. View

12.

Zamora M, Dempsey E, Walchak S, Stelzner T . BQ123, an ETA receptor antagonist, inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol. 1993; 9(4):429-33. DOI: 10.1165/ajrcmb/9.4.429. View

13.

Dupuis J, GORESKY C, Fournier A . Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J Appl Physiol (1985). 1996; 81(4):1510-5. DOI: 10.1152/jappl.1996.81.4.1510. View

14.

Sohn D, Kim H, Kim M, Song Y, Noh C, Kim D . Beneficial and adverse effects of bosentan treatment in korean patients with pulmonary artery hypertension. Korean Circ J. 2009; 39(3):105-10. PMC: 2771800. DOI: 10.4070/kcj.2009.39.3.105. View

15.

Giaid A, Yanagisawa M, Langleben D, Michel R, Levy R, Shennib H . Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993; 328(24):1732-9. DOI: 10.1056/NEJM199306173282402. View

16.

Dai Z, Tan M, Chai C, Chou S, Lin P, Yeh J . Effects of sildenafil on pulmonary hypertension and levels of ET-1, eNOS, and cGMP in aorta-banded rats. Exp Biol Med (Maywood). 2006; 231(6):942-7. View

17.

Todd L, Mullen M, Olley P, Rabinovitch M . Pulmonary toxicity of monocrotaline differs at critical periods of lung development. Pediatr Res. 1985; 19(7):731-7. DOI: 10.1203/00006450-198507000-00019. View

18.

Dupuis J, GORESKY C, Stewart D . Pulmonary removal and production of endothelin in the anesthetized dog. J Appl Physiol (1985). 1994; 76(2):694-700. DOI: 10.1152/jappl.1994.76.2.694. View

19.

Weber C, Schmitt R, Birnboeck H, Hopfgartner G, van Marle S, Peeters P . Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther. 1996; 60(2):124-37. DOI: 10.1016/S0009-9236(96)90127-7. View

20.

Miyauchi T, Yorikane R, Sakai S, Sakurai T, Okada M, Nishikibe M . Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ Res. 1993; 73(5):887-97. DOI: 10.1161/01.res.73.5.887. View